CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymph...
Phase 3
New York, New York, United States and 8 other locations
inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...
Phase 1, Phase 2
New York, New York, United States and 51 other locations
in children with relapsed or refractory acute lymphoblastic leukemia or lymphoma (rALL) and assessing the combination dose of venetoclax com...
Phase 1, Phase 2
New York, New York, United States and 1 other location
in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...
Phase 2
New York, New York, United States and 173 other locations
in treating pediatric and young adult patients with acute myeloid leukemia (AML) or acute leukemia of ambiguous lineage (ALAL) that...
Phase 1
New York, New York, United States and 10 other locations
Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...
Phase 1, Phase 2
New York, New York, United States and 47 other locations
single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML).The dose escalation (Part A) of the study will explor...
Phase 1
New York, New York, United States and 13 other locations
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)...
Phase 1, Phase 2
New York, New York, United States and 8 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
New York, New York, United States and 23 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....
Phase 1
Bronx, New York, United States and 22 other locations
Clinical trials
Research sites
Resources
Legal